

Lindi Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/60048/publications.pdf>

Version: 2024-02-01

91
papers

1,565
citations

393982

19
h-index

377514

34
g-index

98
all docs

98
docs citations

98
times ranked

2161
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a prediction model for glucocorticoid-associated osteonecrosis of the femoral head by targeted sequencing. <i>Rheumatology</i> , 2022, 61, 846-855.	0.9	2
2	A novel model to assess disease activity in Takayasu arteritis based on 18F-FDG-PET/CT: a Chinese cohort study. <i>Rheumatology</i> , 2022, 61, SI14-SI22.	0.9	14
3	Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 117-123.	0.5	31
4	FABP3 overexpression promotes vascular fibrosis in Takayasu's arteritis by enhancing fatty acid oxidation in aorta adventitial fibroblasts. <i>Rheumatology</i> , 2022, 61, 3071-3081.	0.9	9
5	Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study. <i>Clinical Rheumatology</i> , 2022, 41, 731-739.	1.0	2
6	Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. <i>Clinical Rheumatology</i> , 2022, 41, 2121-2128.	1.0	3
7	Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2022, 49, 482-488.	1.0	1
8	A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 49.	1.6	10
9	Deletion of BACH1 Attenuates Atherosclerosis by Reducing Endothelial Inflammation. <i>Circulation Research</i> , 2022, 130, 1038-1055.	2.0	55
10	Eosinophilic granulomatosis with polyangiitis is associated with hepatitis B virus infection. <i>Clinical Rheumatology</i> , 2022, , .	1.0	0
11	Clinical and pathological predictors of relapse in IgG4-related disease. <i>Arthritis Research and Therapy</i> , 2022, 24, 106.	1.6	9
12	Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: A prospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152018.	1.6	11
13	Characteristics and Medium-term Outcomes of Takayasu Arteritis-related Renal Artery Stenosis: Analysis of a Large Chinese Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 87-93.	1.0	8
14	Prognostic factors in IgG4-related disease: a long-term monocentric Chinese cohort study. <i>Clinical Rheumatology</i> , 2021, 40, 2293-2300.	1.0	12
15	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 739-746.	0.5	18
16	Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE. <i>Advances in Therapy</i> , 2021, 38, 772-781.	1.3	5
17	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	2.6	26
18	Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110287.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 63.	1.6	14
20	Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial. <i>Rheumatology and Therapy</i> , 2021, 8, 361-374.	1.1	3
21	Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study. <i>Rheumatology</i> , 2021, 60, 5089-5097.	0.9	18
22	Effect of hydroxychloroquine on angiographic progression in routine treatment of Takayasu arteritis. <i>Modern Rheumatology</i> , 2021, 31, 1135-1141.	0.9	4
23	Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages. <i>Frontiers in Immunology</i> , 2021, 12, 632864.	2.2	7
24	Potential Role of Macrophage Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis. <i>Frontiers in Immunology</i> , 2021, 12, 646516.	2.2	16
25	Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2021, 40, 4117-4126.	1.0	2
26	Epidemiology of Takayasu arteritis in Shanghai: A hospital-based study and systematic review. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1247-1256.	0.9	10
27	Clinical characteristics, imaging phenotypes and events free survival in Takayasu arteritis patients with hypertension. <i>Arthritis Research and Therapy</i> , 2021, 23, 196.	1.6	4
28	Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1631-1633.	0.5	19
29	Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. <i>Joint Bone Spine</i> , 2021, 88, 105186.	0.8	12
30	Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery. <i>Chinese Medical Journal</i> , 2021, 134, 625-627.	0.9	0
31	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 101-106.	0.4	0
32	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 161-170.	0.4	0
33	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 161-170.	0.4	3
34	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 101-106.	0.4	1
35	Single-Cell Analysis Identify Transcription Factor BACH1 as a Master Regulator Gene in Vascular Cells During Aging. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 786496.	1.8	8
36	High melatonin levels are related to spinal ossification in patients with ankylosing spondylitis. <i>Modern Rheumatology</i> , 2020, 30, 373-378.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 59-65.	1.6	19
38	Effectiveness and safety of methotrexate <i>versus</i> leflunomide in 12-month treatment for Takayasu arteritis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097523.	1.1	14
39	Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points. <i>Frontiers in Pharmacology</i> , 2020, 11, 606497.	1.6	2
40	The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. <i>Clinical Rheumatology</i> , 2020, 39, 3417-3425.	1.0	9
41	Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092201.	1.1	10
42	Involvement of the pulmonary arteries in patients with Takayasu arteritis: a prospective study from a single centre in China. <i>Arthritis Research and Therapy</i> , 2020, 22, 131.	1.6	18
43	Efficacy and safety of leflunomide <i>versus</i> cyclophosphamide for initial-onset Takayasu arteritis: a prospective cohort study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093011.	1.2	9
44	In vitro IL-6/IL-6R Trans-Signaling in Fibroblasts Releases Cytokines That May Be Linked to the Pathogenesis of IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1272.	2.2	17
45	Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial. <i>BioDrugs</i> , 2020, 34, 381-393.	2.2	21
46	Advancements in medical and surgical treatments of Takayasu arteritis-induced renal arteritis: a systematic review. <i>Chinese Medical Journal</i> , 2020, 133, 975-981.	0.9	10
47	Potential risk of hyperuricemia: leading cardiomyocyte hypertrophy by inducing autophagy. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 1894-1903.	0.0	0
48	The potential role of leflunomide in inhibiting vascular fibrosis by down-regulating type-II macrophages in Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 69-78.	0.4	2
49	CYR61/TGF- β 2 axis promotes adventitial fibrosis of Takayasu's arteritis in the IL-17 mediated inflammatory microenvironment. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1102-1111.	0.4	2
50	100. <i>EXPLORE THE DIAGNOSTIC CRITERIA FOR TAKAYASU ARTERITIS</i> . <i>Rheumatology</i> , 2019, 58, .	0.9	1
51	YKL-40 as a new biomarker of disease activity in Takayasu arteritis. <i>International Journal of Cardiology</i> , 2019, 293, 231-237.	0.8	12
52	Serum leptin, a potential predictor of long-term angiographic progression in Takayasu's arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 2134-2142.	0.9	5
53	161. <i>AUGMENTED IL-6 IMPLIES UN-SEVERE VASCULAR STENOSIS IN TAKAYASU'S ARTERITIS: A CROSS-SECTIONAL STUDY BASED ON ECTA COHORT</i> . <i>Rheumatology</i> , 2019, 58, .	0.9	0
54	341. <i>LONG-TERM CLINICAL AND SURGICAL OUTCOMES OF TAKAYASU ARTERITIS PATIENTS WITH AORTITIS: CASE SERIES FROM THE EAST CHINA COHORT</i> . <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
55	342.â€fLONG-TERM EFFICACY AND SAFETY OF LEFLUNOMIDE TREATMENT IN TAKAYASU ARTERITIS: CASE SERIES FROM THE EAST CHINA COHORT. <i>Rheumatology</i> , 2019, 58, .	0.9	0
56	A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout. <i>Rheumatology and Therapy</i> , 2019, 6, 543-557.	1.1	6
57	149.â€fPULMONARY PRESENTATIONS IN TAKAYASU ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
58	199.â€fM1-TO-M2 PHENOTYPE SHIFT OF MACROPHAGES IN VASCULAR TISSUE OF TAKAYASU ARTERITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	0
59	Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis. <i>Journal of Autoimmunity</i> , 2019, 99, 39-47.	3.0	23
60	Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 24.	1.6	29
61	Radiology and biomarkers in assessing disease activity in Takayasu arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 53-59.	0.9	11
62	Clinical features and current treatments of adult-onset Still's disease: a multicentre survey of 517 patients in China. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 52-57.	0.4	18
63	18F-FDG-PET/CT: an accurate method to assess the activity of Takayasuâ€™s arteritis. <i>Clinical Rheumatology</i> , 2018, 37, 1927-1935.	1.0	18
64	Analysis of predictive factors for treatment resistance and disease relapse in Takayasuâ€™s arteritis. <i>Clinical Rheumatology</i> , 2018, 37, 2789-2795.	1.0	6
65	Smoking quantity determines disease activity and function in Chinese patients with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2018, 37, 1605-1616.	1.0	11
66	Comparison of bi-exponential and mono-exponential models of diffusion-weighted imaging for detecting active sacroiliitis in ankylosing spondylitis. <i>Acta Radiologica</i> , 2018, 59, 468-477.	0.5	11
67	Remission assessment of rheumatoid arthritis in daily practice in China: a cross-sectional observational study. <i>Clinical Rheumatology</i> , 2018, 37, 597-605.	1.0	21
68	Value of three-dimensional speckle tracking echocardiography to assess left ventricular function in hyperuricemia patients. <i>Clinical Rheumatology</i> , 2018, 37, 2539-2545.	1.0	9
69	Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. <i>International Journal of Cardiology</i> , 2018, 266, 222-228.	0.8	25
70	Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. <i>Clinical and Experimental Hypertension</i> , 2017, 39, 93-99.	0.5	13
71	New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy. <i>Rheumatology International</i> , 2017, 37, 1365-1372.	1.5	12
72	Clinical patterns and characteristics of ankylosing spondylitis in China. <i>Clinical Rheumatology</i> , 2017, 36, 1561-1568.	1.0	25

#	ARTICLE	IF	CITATIONS
73	Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. <i>Rheumatology International</i> , 2017, 37, 2019-2026.	1.5	31
74	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry IX. <i>Chinese Medical Journal</i> , 2017, 130, 1276-1282.	0.9	17
75	The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. <i>PLoS Pathogens</i> , 2017, 13, e1006264.	2.1	121
76	The effects of dopamine receptor 2 expression on B cells on bone metabolism and TNF- α levels in rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 352.	0.8	15
77	A preliminary study of the oral microbiota in Chinese patients with Sjögren's syndrome. <i>Archives of Oral Biology</i> , 2016, 70, 143-148.	0.8	37
78	A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. <i>Clinical Rheumatology</i> , 2016, 35, 2175-2183.	1.0	8
79	Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2016, 35, 685-693.	1.0	28
80	Influence of urate-lowering therapies on renal handling of uric acid. <i>Clinical Rheumatology</i> , 2016, 35, 133-141.	1.0	18
81	Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 560-567.	0.9	22
82	Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 880-885.	0.9	17
83	Chinese Systemic Lupus Erythematosus Treatment and Research Group Registry VI: Effect of Cigarette Smoking on the Clinical Phenotype of Chinese Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0134451.	1.1	21
84	Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. <i>Clinical Rheumatology</i> , 2015, 34, 1605-1611.	1.0	22
85	The E3 Deubiquitinase USP17 Is a Positive Regulator of Retinoic Acid-related Orphan Nuclear Receptor β 3 (ROR β 3) in Th17 Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 25546-25555.	1.6	54
86	Evaluation of Takayasu arteritis activity by delayed contrast-enhanced magnetic resonance imaging. <i>International Journal of Cardiology</i> , 2012, 155, 262-267.	0.8	75
87	MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. <i>International Journal of Cardiology</i> , 2012, 156, 236-238.	0.8	43
88	Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. <i>Journal of Colloid and Interface Science</i> , 2012, 365, 143-149.	5.0	179
89	Evaluation of Clinical Measures and Different Criteria for Diagnosis of Adult-onset Still's Disease in a Chinese Population. <i>Journal of Rheumatology</i> , 2011, 38, 741-746.	1.0	24
90	Hypoparathyroidism in a patient with systemic lupus erythematosus coexisted with ankylosing spondylitis: A case report and review of literature. <i>Joint Bone Spine</i> , 2010, 77, 608-610.	0.8	11

#	ARTICLE	IF	CITATIONS
91	The hepatotoxicity of multi-walled carbon nanotubes in mice. <i>Nanotechnology</i> , 2009, 20, 445101.	1.3	89